Dry antibiotic pipeline: Regulatory bottlenecks and regulatory reforms

Journal of Pharmacology and Pharmacotherapeutics

Volumn 5, Issue 1, 2014, Pages 4-7

  Gupta, Sandeep Kumar ^a   Nayak, Roopa P ^a  

^a Dhanalakshmi Srinivasan Medical College and Hospital   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ORPHAN DRUG;

AREA UNDER THE CURVE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG RESEARCH; DRUG SAFETY; DRUG UTILIZATION; FOOD AND DRUG ADMINISTRATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACEUTICAL EQUIVALENCE; PUBLICATION; REVIEW; TRANSLATIONAL RESEARCH;

EID: 84892682239     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.124405     Document Type: Review

References (14)

1. Talbot GH, Bradley J, Edwards Jr JE, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis 2006. 42:657-68.
2. Charles PG, Grayson ML. The dearth of new antibiotic development: Why we should be worried and what we can do about it. Med J Aust 2004;181:549-53.
3. Gupta SK. Non-inferiority clinical trials: Practical issues and current regulatory perspective. Indian J Pharmacol. 2011;43:371-4.
4. Alvan G, Edlund C, Heddini A. The global need for effective antibiotics: A summary of plenary presentations. Drug Resist Update 2011;14:70-6.
5. Report of the British Society for Antimicrobial Chemotherapy Initiative. The Urgent Need, 2011. Regenerating antibacterial drug discovery development. Downloaded from http://www.antibiotic-action.com/wp-content/uploads/2011/07/TUN- Report.pdf. [Last accessed on 2012 Nov 11].
6. Infectious Diseases Society of America. Bad Bugs, No Drugs. As Antibiotic Discovery Stagnates, A Public Health Crisis Brews, July 2004. Downloaded from http://www.idsociety.org/uploadedFiles/IDSA/Policy-and-Advocacy/ Current-Topics-and-Issues/Antimicrobial-Resistance/1020/Images/ Bad%20Bugs%20no%20Drugs.pdf. [Last accessed on 2012 Nov 1].
7. US Food and Drug Administration. Innovation or Stagnation: Critical Path Opportunities Report and List, March 2006. Downloaded from http://www. fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/ CriticalPathOpportunitiesReports/UCM077254.pdf. [Last accessed on 2012 Oct 30].
8. California Healthcare Institute. Promoting Antibiotic Discovery and Development, A California Healthcare Institute Initiative, 2012. http://www.chi.org/uploadedFiles/Industry-at-a-glance/CHI%20Antibiotic%20 White%20Paper-FINAL.pdf. [Last accessed on 2012 Jul 14].
9. Finch R. Regulatory opportunities to encourage technology solutions to antibacterial drug resistance. J Antimicrob Chemother. 2011;66:1945-7.
10. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Guidance for Industry. Non-Inferiority Clinical Trials. March 2010.
11. International Conference on Harmonisation. Guidance E10: Choice of Control Group and Related Issues in Clinical Trials, July 2000.
12. Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. The importance of pharmacokinetic pharmacodynamic surrogate markers to outcome. Clin Pharmacokinet. 1995;28:143-60.
13. Ambrose PG, et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae. Antimicrob Agents Chemother. 2001;45:2793-7.
14. Food and Drug Administration (FDA) Safety and Innovation Act Antibiotic Incentives. Created by IDSA. September 7, 2012. Downloaded from http://www.idsociety.org/uploadedFiles/IDSA/Policy-and-Advocacy/ Current-Topics-and-Issues/Antimicrobial-Resistance/1020/Letters/To-Congress/ IDSA%20Summary%20of%20Antibiotic%20Incentives%20 in%20FDASIA.pdf. [Last accessed on 2012 Nov 11].